DIABIO — Diagonal Bio AB Share Price
Last trade - 00:00- SEK18.89m
- SEK17.04m
- SEK0.02m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.15 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 913.01 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -58.01% | ||
| Return on Equity | -47.91% | ||
| Operating Margin | -46047.83% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | n/a | 0.02 | 0.41 | 0.2 | 0.02 | n/a | n/a | 4.23% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Diagonal Bio AB is a Sweden-based medical research company. The Company is developing a diagnostic platform (Panviral) for detection of any kind of pathogen. Panviral’s technology is based on rapid isothermal amplification of a pathogen’s genome. Multiple tests can be run in parallel, thereby increasing the sample throughput.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- March 19th, 2020
- Public Since
- July 16th, 2021
- No. of Employees
- 4
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 679,588,243
- Address
- The Spark, Medicon Village, LUND, 223 81
- Web
- https://diagonalbio.com/
- Phone
- Auditors
- MAZARS
Upcoming Events for DIABIO
Similar to DIABIO
2cureX AB
OMX Nordic Exchange Stockholm
Abliva AB
OMX Nordic Exchange Stockholm
Acousort AB
OMX Nordic Exchange Stockholm
Active Biotech AB publ
OMX Nordic Exchange Stockholm
AddLife AB
OMX Nordic Exchange Stockholm
FAQ
As of Today at 20:17 UTC, shares in Diagonal Bio AB are trading at SEK0.03. This share price information is delayed by 15 minutes.
Shares in Diagonal Bio AB last closed at SEK0.03 and the price had moved by -82.3% over the past 365 days. In terms of relative price strength the Diagonal Bio AB share price has underperformed the FTSE Global All Cap Index by -84.43% over the past year.
There is no consensus recommendation for this security.
Diagonal Bio AB does not currently pay a dividend.
Diagonal Bio AB does not currently pay a dividend.
Diagonal Bio AB does not currently pay a dividend.
To buy shares in Diagonal Bio AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of SEK0.03, shares in Diagonal Bio AB had a market capitalisation of SEK21.00m.
Here are the trading details for Diagonal Bio AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: DIABIO
Based on an overall assessment of its quality, value and momentum Diagonal Bio AB is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Diagonal Bio AB. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -86.87%.
As of the last closing price of SEK0.03, shares in Diagonal Bio AB were trading -81.17% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Diagonal Bio AB PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK0.03.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Diagonal Bio AB's directors